Thanks, Rich, everyone. morning, and good
to lead to more critical CDX are continue to response program, have comprehensive advances, immune the any Resting to our T focus beyond PD-X vopra, believe that the role play that levels is and antigen current low express a As active. of not not that been we ICOS exposed cells cancer CDX and of T-cells inhibitors. ICOS
activated CDX We T-cells as antigens hi levels cells they become to of and refer once high T-cells. exposure express ICOS by these to CDX ICOS. are However, primed
either T characterize inhibitors, cells influence cell directly include have and these CDX T-cells. sub-populations. further kill cells not which they that tumor actually that tumor we or to learned helper is cells, PD-X distinct or As on One encourage we emerged through ThX killing three cells CDX have due vopra subset their
is follicular cells. A cells, subset in play role which CDX second production integral antibody T helper an by B
that therapy, long-term is produce from memory, IO which of is vopra important responses. for very to subset, T the by we think cells. benefit memory durable third may The these that able We extend cells be believe expanding central durability immune
is all role our The of ICONIC and central for populations, is role in to with all inhibitor the led and of cell play that may ICOS an complementary demonstration proliferation and these that development represented response, is SELECT from, two benefit their these When durable vopra, the paths associated the but increased by to in through EMERGE which play its PD-X activation trials. upregulated clinical priming, activity. important immune comprehensive sustained cells perhaps three separate on presence
trial. Cells followed hi I of patients experienced would minutes a cell to the cancer. an ipilimumab, to vopra non-small induction spend by EMERGE administration PD-X of T employs ICOS with update EMERGE The on lung in like CDX with few provide trial
to As owing Rich data mentioned, has there and COVID-XX. been an release, on EMERGE impact enrollment
for Our to clinical solutions affairs job, done medical outstanding and delay, minimize ICOS initiation processing critical CDX creative visits have hi operations site our and teams training an PBMC up with on virtual have and virtual biomarker. including come
patients the started to on high progress. enrollment the no when their the to unmet of EMERGE we until number recently very population, study efforts Due screening need impact saw to somewhat. and decrease in continues And in the
complete modest interim delay a but for projecting mid-year enrollment analysis, targeted XXXX. expect We still completing are currently enrollment therefore to to the the
data may last XX you six will analysis response patient the we of recall, interim As which second XXXX. after dataset patients, been not deliver all through clinical enrolled. that in our at the to is on planned include months until And least that be half have weeks approximately biomarker is means data, plus complete the on available to track
scans. the us complete having data with have biomarker early robust recent XXXX. patients the dataset shifted as impact to analysis this to valuable has will the of COVID-XX, least planned our to timeline on-treatment allow two of and preliminary Now Again, efficacy due at into a interim all
data with cancer improvement the brought to starts approval this survival. clinical the brought that understanding the inhibitor, cell EMERGE have in checkpoint would benefits first some the our on patients helpful lung through cancer and the with clinical be with that checkpoint is significant to of next docetaxel it overall nature PD-X outcomes inhibitors As the immunotherapy benefit provide thought benefit durability we non-small second-line of milestone, patients. inhibitors focusing context has From and of to and in clinical
toxicity. of IO than survival. were cell X.X median better second-line on inhibitors on without approved PD-LX In setting, meaningful approximately and of selection in produced docetaxel. based this lung Single-agent biomarker months provides docetaxel, docetaxel were comparison rates rates but marginally PD-LX based in to XX%, PD-X cancer overall to significant non-small response months to six survival X% approved and inhibitors overall PD-X improvements and response naive
by Now, clinical cancer default. outcomes are standard benchmarks patients of PD-X who line lung provide in in second response become non-small let's has to care turn docetaxel no like experienced third in trial where survival There this EMERGE cell and randomized patients data is to and population. the for
is that just feedback population, survival overall in probably suggests in the clinical PD-X I later line and KOL docetaxel, in therapy. as patients expect benefit referenced, from especially one would this likely of no a naive better However, than worse
of duration in patients, we our outcomes clinical to improve durability EMERGE survival. for immunotherapies. Based to ICONIC, potential follow-up share and of critical allow the analysis on into overall these has in built of believe will data these for us combination the the The measures responses durable that vopra including benefit efficacy from on interim
a CDX patients to T the cell XX gene originally predictive I second genes is with IO. T would path, as optimized that and the inhibitor. development an has a using TIS trial now TISvopra medicine CDX believe of vopra SELECT biomarker what and been associated emergence vopra represented includes precision to inhibitors is in PD-X with for we hi for by selection activation turn toward and in treated move prediction signature, the biomarker PD-X developed cell like ICOS
to PD-X approximately second-line randomized our be vopra selected the predictive cell lung enroll to expect We who will biomarker cancer JTX-XXXX naive plus alone. JTX-XXXX, versus TISvopra patients inhibitor, using non-small immunotherapy and XX
will approximately above TISvopra for that of estimate eligible threshold trial. potentially cancer patients non-small be second-line We cell lung and the XX% the
powered the better for selected better be patients, specific to expect cell With with those The plus because superiority vopra the vopra CDX of biomarker, T results hi unselected predictive emergence. demonstrate but vopra is than PD-X JTX-XXXX JTX-XXXX therefore trial TISvopra the in is for even to inhibitors alone. plus ICOS JTX-XXXX for JTX-XXXX we to
position selection We the lines positive believe in may multiple inhibitors of TISvopra partner and as tumor therapy. a types PD-X combination result with that vopra of for choice
this of the As XXXX. resulted three Rich initiation clinical trial. to Despite delay COVID-XX shift, report data a to SELECT select has we months still expect two mentioned, in in in
their Before times. dedication like to turning to unprecedented I proud our helping and the reiterate I despite call am patients these how challenging over and of team and Kim, to community, would our
to to And our precision that it IO patients. to Now coupled more mission approach delivering execute XXXX We to forward progress ever, imperative important this. long-lasting our of us on milestones. science look closer benefit we achieving translational with and upcoming believe is to continued execution our our brings on medicine in than
of our the for turn a to to quarter financial like discussion first Kim? call would I Kim Now, over results.
